Detalhe da pesquisa
1.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35139274
2.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32101663
3.
Alterations in Left Atrial Strain in Breast Cancer Patients Immediately Post Anthracycline Exposure.
Heart Lung Circ
; 2023 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37806911
4.
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
Breast Cancer Res Treat
; 191(3): 501-511, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34853987
5.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-30280658
6.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29658856
7.
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Future Oncol
; 17(10): 1165-1184, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33583206
8.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32035514
9.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artigo
Inglês
| MEDLINE | ID: mdl-28885881
10.
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Lancet Oncol
; 20(12): 1670-1680, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31601496
11.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol
; 20(3): 371-382, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30765258
12.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 375(19): 1823-1833, 2016 11 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27718847
13.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25891174
14.
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Lancet Oncol
; 18(12): 1600-1609, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29129441
15.
Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Eur J Cancer
; 198: 113503, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38134560
16.
The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002-2021): a population-based study.
Lancet Reg Health West Pac
; 45: 101030, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38389934
17.
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
JTO Clin Res Rep
; 5(3): 100638, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38455595
18.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology
; 13(1): 2290787, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38170160
19.
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.
J Transl Med
; 11: 189, 2013 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23945200
20.
Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone.
Australas J Dermatol
; 59(3): e219-e220, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28952146